ASH 2023 | E7820 in combination with venetoclax in patients with splicing factor mutant myeloid malignancies
Jan Philipp Bewersdorf, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the addition of a study arm into a Phase II clinical trial (NCT05024994) of the anti-cancer sulfonamide E7820 in patients with splicing factor mutant myeloid malignancies, such as relapsed/refractory (R/R) acute myeloid (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). Despite having a safety profile, E7820 monotherapy exhibited limited clinical efficacy. Therefore, using compelling preclinical data, Dr Bewersdorf and his team are discussing the addition of an arm that would combine E7820 with the BCL inhibitor venetoclax. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
